Compare Stocks: NBTX, MIRM, ERAS, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$82.37 -0.1%	$103.15	$32.22 ▼ $117.88	$4.51B	1.35	928,467 shs	738,864 shs
ERAS Erasca	$16.03 +3.7%	$16.56	$2.11 ▼ $24.28	$5.61B	0.61	5.91 million shs	7.77 million shs
MIRM Mirum Pharmaceuticals	$86.01 +5.7%	$95.08	$63.23 ▼ $130.00	$5.58B	0.61	854,701 shs	1.14 million shs
NBTX Nanobiotix	$23.68 +3.4%	$36.65	$14.78 ▼ $57.14	$1.20B	0.79	93,132 shs	93,496 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-2.89%	-6.67%	-24.47%	-15.54%	+137.21%
ERAS Erasca	+9.49%	+6.04%	-5.04%	-16.57%	+536.21%
MIRM Mirum Pharmaceuticals	+0.88%	-3.06%	-18.27%	-33.39%	+11.67%
NBTX Nanobiotix	-6.99%	-17.92%	-40.04%	-42.85%	-16.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$82.37 -0.1%	$103.15	$32.22 ▼ $117.88	$4.51B	1.35	928,467 shs	738,864 shs
ERAS Erasca	$16.03 +3.7%	$16.56	$2.11 ▼ $24.28	$5.61B	0.61	5.91 million shs	7.77 million shs
MIRM Mirum Pharmaceuticals	$86.01 +5.7%	$95.08	$63.23 ▼ $130.00	$5.58B	0.61	854,701 shs	1.14 million shs
NBTX Nanobiotix	$23.68 +3.4%	$36.65	$14.78 ▼ $57.14	$1.20B	0.79	93,132 shs	93,496 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-2.89%	-6.67%	-24.47%	-15.54%	+137.21%
ERAS Erasca	+9.49%	+6.04%	-5.04%	-16.57%	+536.21%
MIRM Mirum Pharmaceuticals	+0.88%	-3.06%	-18.27%	-33.39%	+11.67%
NBTX Nanobiotix	-6.99%	-17.92%	-40.04%	-42.85%	-16.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	57.62% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	37.81% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$143.81	67.20% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$46.67	97.07% Upside

Current Analyst Ratings Breakdown

Latest NBTX, MIRM, ERAS, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$135.00 ➝ $155.00
9/29/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$123.00 ➝ $130.00
9/28/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$144.00
9/28/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00 ➝ $160.00
9/28/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $195.00
9/15/2026	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$64.00
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$1.90M	2,370.65	N/A	N/A	$11.41 per share	7.22
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
MIRM Mirum Pharmaceuticals	$618.07M	9.04	$0.05 per share	1,581.82	$6.12 per share	14.05
NBTX Nanobiotix	$8.36M	143.42	N/A	N/A	($1.97) per share	-12.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
NBTX Nanobiotix	-$27.11M	N/A	N/A	148.00	N/A	N/A	N/A	N/A	N/A

Latest NBTX, MIRM, ERAS, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DNTH Dianthus Therapeutics	-$0.9434	N/A	N/A	N/A	$0.44 million	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.53	N/A	N/A	N/A	$178.06 million	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
ERAS Erasca	N/A	8.29	8.29
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
NBTX Nanobiotix	N/A	1.44	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
ERAS Erasca	67.78%
MIRM Mirum Pharmaceuticals	N/A
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
ERAS Erasca	14.20%
MIRM Mirum Pharmaceuticals	8.32%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
NBTX Nanobiotix	97	50.62 million	48.87 million	Not Optionable

NBTX, MIRM, ERAS, and DNTH Headlines

Recent News About These Companies

H.C. Wainwright Reaffirms Their Buy Rating on Nanobiotix (0QAV)

October 6 at 1:48 PM | theglobeandmail.com

Nanobiotix S.A.: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

October 2, 2026 | finanznachrichten.de

Nanobiotix Names Arnd Christ CFO As Rhijn Steps Down

October 2, 2026 | rttnews.com

Nanobiotix Appoints Arnd Christ as CFO

October 1, 2026 | finance.yahoo.com

NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

October 1, 2026 | globenewswire.com

Nanobiotix (NASDAQ:NBTX) Shares Down 4.3% - Time to Sell?

October 1, 2026 | americanbankingnews.com

HC Wainwright Decreases Earnings Estimates for Nanobiotix

September 29, 2026 | americanbankingnews.com

Can J&J’s Partnership Drive More Upside for Nanobiotix?

September 28, 2026 | insidermonkey.com

Nanobiotix FY2027 Earnings Forecast Lowered by HC Wainwright

September 28, 2026 | americanbankingnews.com

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

September 24, 2026 | globenewswire.com

Voting Rights and Shares Capital of the Company

September 22, 2026 | globenewswire.com

Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?

September 17, 2026 | finance.yahoo.com

Nanobiotix reports 79% one-year control with JNJ-1900

September 14, 2026 | grafa.comG

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

September 14, 2026 | globenewswire.com

Nanobiotix (NASDAQ:NBTX) Stock Price Up 4.6% - Time to Buy?

September 10, 2026 | marketbeat.com

NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | globenewswire.com

Voting Rights and Shares Capital of the Company

August 25, 2026 | globenewswire.com

Nanobiotix SA Sponsored ADR

August 12, 2026 | edition.cnn.com

Voting Rights and Shares Capital of the Company

July 30, 2026 | globenewswire.com

Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026

July 6, 2026 | theglobeandmail.com

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

June 25, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, MIRM, ERAS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$82.37 -0.06 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$82.34 -0.03 (-0.03%)

As of 07:32 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca NASDAQ:ERAS

$16.03 +0.57 (+3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$15.64 -0.39 (-2.43%)

As of 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$86.01 +4.66 (+5.73%)

Closing price 04:00 PM Eastern

Extended Trading

$85.98 -0.04 (-0.04%)

As of 07:41 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Nanobiotix NASDAQ:NBTX

$23.68 +0.78 (+3.41%)

Closing price 04:00 PM Eastern

Extended Trading

$23.72 +0.04 (+0.15%)

As of 07:30 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBTX, MIRM, ERAS, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBTX, MIRM, ERAS, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBTX, MIRM, ERAS, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, MIRM, ERAS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Nanobiotix NASDAQ:NBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBTX, MIRM, ERAS, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBTX, MIRM, ERAS, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBTX, MIRM, ERAS, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, MIRM, ERAS, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Nanobiotix NASDAQ:NBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools